3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Sarcoma
7
Sarcoma, Ewing
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Osteosarcoma
3
Lymphoma, Large B-Cell, Diffuse
3
Sarcoma, Clear Cell
2
Rhabdomyosarcoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neurofibrosarcoma
2
Nerve Sheath Neoplasms
2
Lymphoma
2
Liposarcoma
2
Hodgkin Disease
2
Histiocytoma, Angiomatoid Fibrous
2
Granuloma, Plasma Cell
2
Fibrosarcoma
2
Dermatofibrosarcoma
2
Chondrosarcoma, Extraskeletal Myxoid
2
Wilms Tumor
1
Vascular Neoplasms
1
Teratoma
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Pleuropulmonary blastoma
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms, Adipose Tissue
1
Interventions
Cyclophosphamide
28
Rituximab
23
fludarabine
14
fludarabine phosphate
12
Specimen Handling
11
obinutuzumab
10
ibrutinib
10
Magnetic Resonance Spectroscopy
10
Prednisone
8
Doxorubicin
8
tocilizumab
7
polatuzumab vedotin
7
X-Rays
7
Whole-Body Irradiation
7
Phantoms, Imaging
7
Mycophenolic Acid
7
Etoposide
7
Biopsy
7
venetoclax
6
glofitamab
6
Melphalan
6
Lenalidomide
6
Bendamustine Hydrochloride
6
pirtobrutinib
5
acalabrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Gemcitabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Ifosfamide
×
90 days
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled